# A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer

> **NCT07278336** · PHASE1 · RECRUITING · sponsor: **AbbVie** · enrollment: 207 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** ABBV-901
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07278336
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-27
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 207 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07278336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07278336, "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT07278336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*